Agenus Inc. Reports Q3 2025 Financial and Clinical Progress
I'm PortAI, I can summarize articles.
Agenus Inc. (AGEN) reported its Q3 2025 earnings, highlighting significant clinical advancements, including the initiation of a global Phase 3 trial for its BOT/BAL therapy in refractory colorectal cancer. The company achieved a net income due to the deconsolidation of MiNK and secured a $10 million bridge facility from Zydus. Promising survival rates were noted for BOT/BAL in advanced solid tumors. Agenus is focused on expanding patient access and advancing its clinical programs, with key milestones expected in the coming months.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments